Aktuellt
SENASTE
Redeye sees a "return to the roots" for Orexo, with the new drug delivery technology and two pharmaceutical drug candidates for two large indications with an urgent need. While it is early to include the new OX640 product in our valuation, Orexo strengthens our confidence in its ability to innovate and create value for investors.
LÄS MER
